Clinical Trials
10 trialsNCT03712904 2025-09-24
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT03710564 2023-01-30
MERLIN
Novartis
Phase 3 Terminated
NCT00437034 2021-02-08
Aflibercept for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00794417 2020-12-10
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT01669720 2020-02-17
C261
Brown University
Phase 2 Terminated
NCT02192541 2018-03-29
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02045030 2016-11-16
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
Phase 2 Terminated
NCT00574275 2016-06-07
VANILLA
Sanofi
Phase 3 Terminated
NCT01955629 2016-04-18
AMOR
Sanofi
Phase 1/2 Terminated
NCT00509249 2015-01-08
Aflibercept in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2 Terminated